Monthly Formulary Amendments – August 2022
Monthly Formulary Amendments Documents list any NICE Technology Appraisals, NICE Guidelines, RMOC Guidance, MHRA Drug Safety Updates, and National Patient Safety Alerts published in the previous calendar month which may have an impact on local formularies and guidelines. This document is for APCs, and formulary committees to ensure formularies remain up to date, and in line with latest NICE guidance and safety information.
This edition covers guidance and alerts published in August 2022.
It includes a suggested formulary position for APCs/formulary committees, together with a summary of any financial/commissioning implications. The purpose of the document is to support consistent decision making by APCs.
This information is produced for use by NHS healthcare professionals and RDTC stakeholders.
Prescribing Update Newsletter – August 2022
Prescribing support newsletters aim to inform readers of work done by the unit and work in progress, to help tailor local work plans and highlight any ‘topical’ issues in prescribing or medicines management.
If you have any suggestions for future topics for the newsletter, then please contact nuth.nyrdtc.rxsupp@nhs.net
This month’s edition introduces Strategic Insights, our new publication type, and has the first in a series of “Meet the Team”, where you can get to know the people behind the work we do. We also cover the new national shared care protocols published by NHSE, changes to the childhood vaccination schedule, and outline some resources that are available to support DOAC switches. There is also information on the changes to the Medicines Information Service, and some key medicines availability issues.
Monthly Horizon Scanning Report – August 2022
Monthly horizon scanning reports are designed to inform the NHS about new products, significant changes to product licenses, significant new guidance, and decisions that have been made by recognised bodies.
This information is produced for use by NHS healthcare professionals.
Omalizumab and dupilumab for chronic rhinosinusitis with nasal polyps
Overview
Evaluation reports aim to give objective information and guidance on medicines and medical devices to commissioners of health services, prescribers and others. They include efficacy, adverse effects, place in treatment and arrangements for prescribing.
Omalizumab and dupilumab are indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe chronic rhinosinusitis with nasal polyps (CRSwNP). This publication reviews their efficacy and safety, and the limitations of the evidence.
Switch Saving Calculators
Overview
These calculators illustrate potential savings from selected changes in prescribing. Many of the examples shown involve relatively simple switches from one formulation to another, with no change in drug or total daily dose. Others show the savings that could be made from switching to effective alternatives from the same therapeutic class.
Frequency
Quarterly
Data period
August 2021
Monthly Horizon Scanning Report – August 2021
Monthly horizon scanning reports are designed to inform the NHS about new products, significant changes to product licenses, significant new guidance, and decisions that have been made by recognised bodies
This information is produced for use by NHS healthcare professionals.
Atrial Fibrillation [NICE NG196]: Financial and commissioning impact
In April 2021, NICE published a new guideline NG196 – Atrial fibrillation: diagnosis and management which updates and replaces NICE CG180 (2014). There are a number of new recommendations, which are likely to have both a significant financial impact and potentially affect the way anticoagulation monitoring is managed. This bulletin aims to raise awareness of the commissioning and financial impact of this new guideline.
There are five versions of this publication; please select the appropriate version for your region below.